JP2011501959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501959A5 JP2011501959A5 JP2010532056A JP2010532056A JP2011501959A5 JP 2011501959 A5 JP2011501959 A5 JP 2011501959A5 JP 2010532056 A JP2010532056 A JP 2010532056A JP 2010532056 A JP2010532056 A JP 2010532056A JP 2011501959 A5 JP2011501959 A5 JP 2011501959A5
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- fusion protein
- seq
- fragment
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010088751 Albumins Proteins 0.000 claims 105
- 102000009027 Albumins Human genes 0.000 claims 105
- 108020001507 fusion proteins Proteins 0.000 claims 47
- 102000037865 fusion proteins Human genes 0.000 claims 47
- 150000001413 amino acids Chemical group 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims 14
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 14
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000035475 disorder Diseases 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 229960003920 cocaine Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 241000972773 Aulopiformes Species 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 101000693916 Gallus gallus Albumin Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 101000930455 Ovis aries Albumin Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000008784 apnea Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000001784 detoxification Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 235000019515 salmon Nutrition 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003162 Arterial injury Diseases 0.000 claims 1
- 102000021944 Butyrylcholinesterase Human genes 0.000 claims 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038540 Renal tubular necrosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 208000033774 Ventricular Remodeling Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/932,823 US20080194481A1 (en) | 2001-12-21 | 2007-10-31 | Albumin Fusion Proteins |
| PCT/US2008/012306 WO2009058322A1 (en) | 2007-10-31 | 2008-10-30 | Albumin fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013233069A Division JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501959A JP2011501959A (ja) | 2011-01-20 |
| JP2011501959A5 true JP2011501959A5 (cg-RX-API-DMAC7.html) | 2011-12-15 |
Family
ID=40591364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532056A Pending JP2011501959A (ja) | 2007-10-31 | 2008-10-30 | アルブミン融合タンパク質 |
| JP2013233069A Active JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013233069A Active JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20080194481A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2211888A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2011501959A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008319332B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2703943A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL204839A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009058322A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1803730A1 (en) | 2000-04-12 | 2007-07-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| WO2004096113A2 (en) * | 2003-04-28 | 2004-11-11 | Medical Instill Technologies, Inc. | Container with valve assembly for filling and dispensing substances, and apparatus and method for filling |
| EP3404102B1 (en) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| US9222728B2 (en) | 2006-04-24 | 2015-12-29 | Medinstill Development Llc | Penetrable and resealable lyophilization device |
| EP2046367A4 (en) * | 2006-06-07 | 2009-11-11 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| JP2011528332A (ja) * | 2008-07-18 | 2011-11-17 | ノボザイムス アデニウム バイオテック アクティーゼルスカブ | 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 |
| BRPI0915778A2 (pt) * | 2008-07-18 | 2019-09-24 | Novozymes Adenium Biotech As | uso de uma beta defensiva humana |
| CA2750727A1 (en) * | 2008-07-18 | 2010-01-21 | Novozymes Adenium Biotech A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
| JP2013502458A (ja) | 2009-08-24 | 2013-01-24 | アムニクス オペレーティング インコーポレイテッド | 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法 |
| MX2012006462A (es) | 2009-12-08 | 2012-10-03 | Teva Pharma | Fusiones de albumina bche para el tratamiento de abuso de cocaina. |
| ES2678144T3 (es) | 2010-02-16 | 2018-08-09 | Medimmune, Llc | Composiciones relacionadas con SAH y métodos de uso |
| US9266939B2 (en) | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| KR20140012094A (ko) * | 2011-02-15 | 2014-01-29 | 메디뮨 엘엘씨 | Hsa 관련 조성물 및 사용 방법 |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| US20120277155A1 (en) | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| CN107261119A (zh) * | 2011-02-28 | 2017-10-20 | 独立行政法人国立循环器病研究中心 | 恶性肿瘤转移抑制用药物 |
| EP3527218A1 (en) | 2011-06-10 | 2019-08-21 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
| RU2642310C2 (ru) | 2011-06-28 | 2018-01-24 | ИНХИБРКС ЭлЭлСи | Слитые серпиновые полипептиды и способы их применения |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
| WO2013033675A1 (en) | 2011-09-02 | 2013-03-07 | Medtronic, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
| KR102212098B1 (ko) | 2012-01-12 | 2021-02-03 | 바이오버라티브 테라퓨틱스 인크. | 키메라 인자 viii 폴리펩티드들과 이의 용도 |
| JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第ｖｉｉｉ因子タンパク質 |
| MX369862B (es) | 2012-02-15 | 2019-11-25 | Bioverativ Therapeutics Inc | Composiciones del factor viii y metodos para hacerlas y usarlas. |
| IN2014MN02089A (cg-RX-API-DMAC7.html) | 2012-03-20 | 2015-09-11 | Einstein Coll Med | |
| CN112142855A (zh) * | 2012-05-18 | 2020-12-29 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| EP4079316A1 (en) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| JP2015525222A (ja) | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | キメラ性凝固因子 |
| EA201792485A3 (ru) | 2012-07-11 | 2019-03-29 | Амуникс Оперэйтинг Инк. | Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты) |
| US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| AU2013331000B2 (en) | 2012-10-18 | 2018-04-19 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| US10772940B1 (en) | 2012-12-11 | 2020-09-15 | University Of Kentucky Research Foundation | Cocaine hydrolase-FC fusion proteins for cocaine and methods for utilizing the same |
| WO2014113359A1 (en) * | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
| PL2956477T5 (pl) | 2013-02-15 | 2024-05-27 | Bioverativ Therapeutics Inc. | Zoptymalizowany gen czynnika viii |
| EP3318124A3 (en) | 2013-02-16 | 2018-05-30 | Albumedix A/S | Pharmacokinetic animal model |
| US20160152686A1 (en) | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
| SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| US20160251408A1 (en) | 2013-06-28 | 2016-09-01 | Biogen Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
| US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| EP3903599A1 (en) | 2013-09-25 | 2021-11-03 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| MY204756A (en) | 2014-01-10 | 2024-09-11 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
| WO2015168284A1 (en) * | 2014-04-30 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Albumin-bche in detoxification of neurotoxins |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| KR20170062490A (ko) | 2014-09-26 | 2017-06-07 | 바이엘 파마 악티엔게젤샤프트 | 안정화된 아드레노메둘린 유도체 및 그의 용도 |
| PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| EP3226891B1 (en) | 2014-12-05 | 2025-06-25 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| HK1257341A1 (zh) | 2015-08-17 | 2019-10-18 | Alexion Pharmaceuticals, Inc. | 硷性磷酸酯的制造 |
| US10016502B2 (en) * | 2015-08-29 | 2018-07-10 | Medrx Co., Ltd | Patch preparation containing an acid scavenger |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| RS63548B1 (sr) | 2016-02-01 | 2022-09-30 | Bioverativ Therapeutics Inc | Optimizovani geni faktora viii |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| CN109152820A (zh) | 2016-04-01 | 2019-01-04 | 阿雷克森制药公司 | 用碱性磷酸酶治疗肌肉无力 |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| US20210333279A1 (en) | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| CA3044838A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| CN110520150A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 使用嵌合凝血因子治疗血友病性关节病的方法 |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3562840A1 (en) | 2016-12-16 | 2019-11-06 | Biogen MA Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
| WO2018213766A1 (en) * | 2017-05-19 | 2018-11-22 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for improving cognition |
| KR20250040746A (ko) | 2017-08-09 | 2025-03-24 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 이의 용도 |
| CN111918674A (zh) | 2018-02-01 | 2020-11-10 | 比奥维拉迪维治疗股份有限公司 | 表达因子viii的慢病毒载体的用途 |
| BR112020018709A2 (pt) | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| LT3793588T (lt) | 2018-05-18 | 2025-06-25 | Bioverativ Therapeutics Inc. | Hemofilijos a gydymo būdai |
| BR112020026512A2 (pt) | 2018-07-03 | 2021-04-06 | Bristol-Myers Squibb Company | Formulações de fgf-21 |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| SG11202105880TA (en) | 2018-12-06 | 2021-07-29 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor ix |
| JP2022536474A (ja) * | 2019-06-10 | 2022-08-17 | アクセス ツー アドバンスト ヘルス インスティチュート | アストロウイルスレプリコンの方法および組成物 |
| CA3143584A1 (en) | 2019-06-18 | 2020-12-24 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| AU2020398898A1 (en) | 2019-12-09 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| BR112022026127A2 (pt) | 2020-06-24 | 2023-01-17 | Bioverativ Therapeutics Inc | Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína |
| CN112725305B (zh) * | 2021-01-13 | 2022-11-04 | 云南师范大学 | 热盐性敏感的菊粉酶突变体MutY119D及其制备方法 |
| CN117042791A (zh) | 2021-02-12 | 2023-11-10 | 阿雷克森制药公司 | 碱性磷酸酶多肽及其使用方法 |
| CN119823285B (zh) * | 2025-01-09 | 2025-08-19 | 石家庄市农林科学研究院 | 一种貉α干扰素和β防御素融合蛋白及其编码基因和应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5514567A (en) * | 1979-01-30 | 1996-05-07 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US5326859A (en) * | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US4530901A (en) * | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4456748A (en) * | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| JPS60136596A (ja) * | 1983-12-26 | 1985-07-20 | Suntory Ltd | ペプチド及びこれを有効成分とする利尿剤 |
| US4716217A (en) * | 1984-08-31 | 1987-12-29 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
| US4734491A (en) * | 1984-08-31 | 1988-03-29 | University Patents, Inc. | DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5002764A (en) * | 1986-08-12 | 1991-03-26 | Schering Corporation | Treatment of actinic keratoses with alpha2 interferon |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| WO1994003198A1 (en) | 1992-07-31 | 1994-02-17 | Genentech, Inc. | Human growth hormone aqueous formulation |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| IL90730A0 (en) | 1988-06-24 | 1990-01-18 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| PT90959B (pt) | 1988-06-24 | 1995-05-04 | Dow Chemical Co | Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| EP0387319B1 (en) | 1988-07-23 | 1996-03-06 | Delta Biotechnology Limited | Secretory leader sequences |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| US5173408A (en) | 1989-11-13 | 1992-12-22 | Lange Louis George Iii | Mammalian pancreatic cholesterol esterase |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07108232B2 (ja) | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
| WO1992009691A1 (fr) * | 1990-11-29 | 1992-06-11 | Institut National De La Recherche Agronomique - I.N.R.A. | Nouveaux variants derives des interferons de type i, leur procede de production, et leurs applications |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5540923A (en) * | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5932780A (en) | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US5695750A (en) * | 1994-11-25 | 1997-12-09 | The United States Of America As Represented By The Secretary Of The Army | Compositions for use to deactivate organophosphates |
| US5480640A (en) * | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| US6001625A (en) * | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP0904373A1 (en) * | 1996-03-14 | 1999-03-31 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
| WO1998012344A1 (en) | 1996-09-18 | 1998-03-26 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
| EP1803730A1 (en) * | 2000-04-12 | 2007-07-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ATE406384T1 (de) | 2000-12-07 | 2008-09-15 | Lilly Co Eli | Glp-1 fusion proteine |
| WO2002064796A2 (en) * | 2000-12-26 | 2002-08-22 | Applied Molecular Evolution, Inc. | Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| US7070973B2 (en) * | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
| US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US7049121B2 (en) * | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003054182A2 (en) * | 2001-12-21 | 2003-07-03 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US20060253913A1 (en) * | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| EP1594530A4 (en) * | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| EP1729795B1 (en) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| BRPI0614761A2 (pt) | 2005-08-12 | 2009-05-19 | Human Genome Sciences Inc | proteìnas de fusão de albumina |
| CA2562249A1 (en) * | 2005-10-20 | 2007-04-20 | University Of Ottawa Heart Institute | Anf analogue |
| EP2046367A4 (en) | 2006-06-07 | 2009-11-11 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
-
2007
- 2007-10-31 US US11/932,823 patent/US20080194481A1/en not_active Abandoned
-
2008
- 2008-10-30 CA CA2703943A patent/CA2703943A1/en not_active Abandoned
- 2008-10-30 AU AU2008319332A patent/AU2008319332B2/en active Active
- 2008-10-30 WO PCT/US2008/012306 patent/WO2009058322A1/en not_active Ceased
- 2008-10-30 JP JP2010532056A patent/JP2011501959A/ja active Pending
- 2008-10-30 EP EP08843705A patent/EP2211888A4/en not_active Withdrawn
-
2010
- 2010-04-06 IL IL204839A patent/IL204839A0/en unknown
- 2010-06-03 US US12/793,658 patent/US8287859B2/en not_active Expired - Lifetime
-
2013
- 2013-11-11 JP JP2013233069A patent/JP5856131B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501959A5 (cg-RX-API-DMAC7.html) | ||
| US20200181216A1 (en) | Hsa-gdf-15 fusion polypeptide and use thereof | |
| CN101389648B (zh) | 肽胃泌酸调节素衍生物 | |
| TWI760333B (zh) | Ｇｄｆ１５融合蛋白及其用途 | |
| CN101367873B (zh) | 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用 | |
| CN102197049B (zh) | 胰岛淀粉样多肽衍生物 | |
| JP2012529297A5 (cg-RX-API-DMAC7.html) | ||
| EP2094288A2 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| MX2014000031A (es) | Polipeptidos de fusion de relaxina y usos de los mismos. | |
| CN108473546B (zh) | Mg53突变体及其制备方法和用途 | |
| CN102153652A (zh) | 一种融合蛋白的表达方法及用途 | |
| JP2007521807A5 (cg-RX-API-DMAC7.html) | ||
| JP2013545724A (ja) | 作用持続時間が増した改変ポリペプチド | |
| JP2013536254A (ja) | インターロイキン−２２のウイルス性肝炎の治療における応用 | |
| CN106432509B (zh) | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 | |
| CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
| JP2012511506A (ja) | 新規インスリンアナログ | |
| US8008257B2 (en) | ANF fusion proteins | |
| WO1997038014A1 (en) | Fibulin pharmaceutical compositions and related methods | |
| JP6612360B2 (ja) | 薬用作用を有する融合タンパク質複合体および融合タンパク質 | |
| JP2013520166A5 (cg-RX-API-DMAC7.html) | ||
| KR102700862B1 (ko) | apoC-II 모방 펩타이드 | |
| JP2024517967A (ja) | 修飾ｂ型ナトリウム利尿ペプチド | |
| CN103159847A (zh) | 一种利钠肽及其基因与用途 | |
| RU2369404C2 (ru) | Слитые белки альбумина |